Depression treatment for Lake Worth Beach — the full escalation pathway, 22 minutes away.

RECO Integrated Psychiatry sits 14 miles south of Lake Worth Beach — a 22-minute drive down A1A or I-95 from Bryant Park or downtown Lake Worth to our Delray campus. Every depression treatment plan is anchored to a DSM-5-TR diagnosis, a baseline PHQ-9, and a defined algorithm for adequate SSRI or SNRI trials, augmentation with aripiprazole, lithium, or T3, and interventional escalation to TMS or Spravato when pharmacology alone doesn't produce remission. Telepsychiatry covers stable follow-ups so the commute is reserved for the visits that require it.

Lake Worth Beach sits fourteen miles up A1A from RECO Integrated Psychiatry’s Delray Beach office — twenty-two minutes on a clear morning, closer to forty during season. For adults in Bryant Park, College Park, Mango Groves, Parrot Cove, and downtown Lake Worth working through a depressive episode that primary care hasn’t fully resolved, specialist psychiatric care a few exits south keeps the clinical work close without pulling the week apart. Most clients commute in for medication visits or a TMS course and use telepsychiatry for stable follow-ups.

The diagnostic questions primary care doesn’t ask

Before treating “depression” as a monotherapy target, the psychiatric evaluation has to rule out what looks like unipolar depression but isn’t. Bipolar spectrum illness is the most consequential miss: antidepressant monotherapy in unrecognized bipolar disorder can induce mixed states, hypomanic switches, and rapid cycling that make the underlying course of illness harder to treat for years afterward. RECO’s intake screens with the Mood Disorder Questionnaire (MDQ) and HCL-32 alongside a structured mood history — age of first episode, family history of bipolar illness or completed suicide, past response to antidepressants, seasonal patterning.

Other conditions present as depression and require the underlying diagnosis to be treated instead of layered SSRIs. Untreated obsessive-compulsive disorder scores in the moderate-to-severe range on the YBOCS while the client reports the affective symptoms first. PTSD flattens presentation until trauma-focused work with EMDR or prolonged exposure is added. Adult ADHD — screened with the ASRS — produces a demoralization that reads clinically as depression until the executive dysfunction is treated on its own axis. Hypothyroidism, chronic sleep deprivation, and active substance use each require their own workup before an antidepressant algorithm is worth starting.

The initial evaluation is structured to catch these misdiagnoses at intake, not on trial four, when the chart already has three failed SSRIs and a decade of frustration attached to them.

First-line pharmacotherapy done well

A first-line antidepressant trial is defined by two variables: an adequate dose and an adequate duration. RECO’s depression treatment protocol starts most clients on an SSRI — sertraline, escitalopram, or fluoxetine — or an SNRI where pain, fatigue, or anxious features tilt the choice toward venlafaxine XR or duloxetine. Starting doses are titrated to therapeutic range within two to four weeks; the trial then continues at that dose for a full six to eight weeks before response is judged against a repeated PHQ-9.

Where sexual side effects, sedation, or weight gain rule out an SSRI, bupropion is a first-line alternative — particularly for anergic, low-motivation presentations without prominent anxiety. Mirtazapine anchors treatment for insomnia-predominant depression and for clients whose appetite has collapsed. For anxious depression, an SSRI is usually the backbone, with short-course buspirone or hydroxyzine bridging activation-related anxiety in the first two weeks.

Adequate dose and documented duration are the two things commercial insurance requires before it will authorize TMS or Spravato later — and the two things scattered outpatient histories almost never capture. Careful documentation early is what makes escalation possible later.

Augmentation and switching after partial response

Most clients on a first antidepressant improve, but a large minority land in the partial-responder category — meaningful PHQ-9 reduction without remission. The evidence favors augmentation over switching at this decision point, provided the current agent is tolerated. First-line augmentation strategies with the strongest randomized-trial support are aripiprazole (2–15 mg), lithium (targeting a serum level of 0.4–0.8 mEq/L for augmentation, not the 0.6–1.0 mEq/L range used in bipolar maintenance), and low-dose T3 (25–50 mcg). Quetiapine XR and olanzapine are options where sedation and anxious rumination are prominent, weighed against metabolic burden.

Bupropion augmentation is used for residual anergia and fatigue on an SSRI backbone, and can also address SSRI-emergent sexual side effects. For non-responders — clients with no meaningful movement on the PHQ-9 after an adequate trial — a within-class SSRI-to-SSRI switch has limited evidence; a cross-class switch to an SNRI or to bupropion is better supported. Concurrent CBT or behavioral activation is layered in where the depressive cognition and inertia are driving the residual symptoms, and ACT or MI are used where values-based engagement and ambivalence about treatment are the bottleneck.

The interventional escalation pathway

After two adequate antidepressant trials at adequate dose and duration, a client meets the standard clinical definition of treatment-resistant depression — and, for most commercial plans, coverage criteria for TMS and esketamine (Spravato). RECO’s protocol names the escalation option at trial two rather than at trial four or five, so clients don’t spend eighteen months cycling through medication combinations that have already stopped moving the PHQ-9.

Repetitive transcranial magnetic stimulation (rTMS) is offered for clients who prefer a non-medication interventional path — a typical acute course delivers approximately 3,000 pulses per session at 120% of resting motor threshold to the left dorsolateral prefrontal cortex, five days a week for six weeks, followed by a taper. Spravato is used where a REMS-monitored, rapid-response option is the better fit — particularly for clients with active suicidal ideation, where waiting six weeks for an oral response is not clinically acceptable. IV ketamine is available as a cash-pay option for compressed schedules where Spravato’s REMS session structure doesn’t work.

What to expect on your first visit

The initial psychiatric evaluation runs 60–90 minutes. It includes a structured diagnostic interview built around DSM-5-TR criteria, a mood-disorder screen (MDQ, HCL-32), a PHQ-9 and GAD-7, an ASRS where adult ADHD is on the differential, and a substance use history. Prior treatment records — every antidepressant tried, dose reached, duration, and reason for stopping — are gathered before the visit where possible, because that history determines which algorithm branch the treatment plan lives on.

The visit ends with a written plan: a working diagnosis, a specific first-line medication with target dose and titration schedule, a follow-up cadence (typically two to four weeks initially), and the defined criterion for when the plan moves to augmentation or interventional care. Telepsychiatry follow-ups are available for Lake Worth Beach clients whose schedules make weekly Delray visits impractical between titration steps.

Insurance and admissions from Lake Worth Beach

RECO Integrated Psychiatry is in-network with most major commercial plans, including Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans across state lines. Coverage is verified before the first visit, with out-of-pocket cost and prior-authorization requirements confirmed in writing rather than estimated at the front desk.

Spravato and TMS require documented trial history for coverage. The intake team walks Lake Worth Beach clients through which records to request from prior prescribers — dose reached, weeks at that dose, side-effect profile, reason for discontinuation — so authorization is a two-week process rather than a three-month back-and-forth. Where prior records are incomplete, ongoing trials at RECO are documented to the standard commercial payers require, so no future escalation is blocked on paperwork.

Serving residents of: Bryant Park, College Park, Mango Groves, Parrot Cove, downtown Lake Worth.